我武生物2月25日获融资买入1341.55万元，融资余额4.63亿元

Core Insights - Iwubio's stock price increased by 0.11% on February 25, with a trading volume of 141 million yuan, and a net financing buy of -356,700 yuan for the day [1] - The company reported a revenue of 853 million yuan for the first nine months of 2025, representing a year-on-year growth of 16.86%, and a net profit of 345 million yuan, up 26.67% [2] Financing and Margin Trading - On February 25, Iwubio had a total financing and margin trading balance of 465 million yuan, with financing buy of 13.42 million yuan and a financing repayment of 13.77 million yuan [1] - The current financing balance of 463 million yuan accounts for 3.23% of the circulating market value, which is above the 90th percentile of the past year [1] - The margin trading data shows that 16,300 shares were sold short on February 25, with a total value of 446,000 yuan, and a margin balance of 1.44 million yuan, exceeding the 70th percentile of the past year [1] Shareholder Information - As of September 30, 2025, Iwubio had 32,400 shareholders, a decrease of 6.22% from the previous period, while the average circulating shares per person increased by 6.63% to 14,927 shares [2] - The company has distributed a total of 965 million yuan in dividends since its A-share listing, with 369 million yuan distributed in the last three years [3] - Notable institutional shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 1.45 million shares, and new entrants such as Harvest Mutual Fund and Penghua Medical Technology Fund [3]